Swiss National Bank
DOVA

Swiss National Bank’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Swiss National Bank’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-22,000
Closed -$196K – 2594
2019
Q1 		$196K Hold
22,000
– – ﹤0.01% 2496
2018
Q4 		$167K Hold
22,000
– – ﹤0.01% 2525
2018
Q3 		$461K Hold
22,000
– – ﹤0.01% 2430
2018
Q2 		$658K Buy
+22,000
New +$599K ﹤0.01% 2367

Other funds holding DOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Swiss National Bank's DOVA Position: Q2 2019 in Review

Swiss National Bank sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q2 2019, closing a stake of 22,000 shares — an estimated $196K sold.

Swiss National Bank first reported a position in DOVA in Q2 2018 and held it in 4 quarters. The position peaked at $658K in Q2 2018. 66 funds tracked by Wall St. Rank hold DOVA as of Q2 2019.

  • Swiss National Bank reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Swiss National Bank sold 22,000 Dova Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $196K.
  • Swiss National Bank first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 4 quarters.
  • Swiss National Bank's Dova Pharmaceuticals, Inc. Common Stock position peaked at $658K in Q2 2018.
  • 66 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Swiss National Bank's 13F filing for Q2 2019, filed 2 Aug 2019.